http://orcid.org/0000-0001-7263-0229
References
- The United States (US) Centers for Disease Control and Prevention (CDC) first report on antibiotic resistance threats in the US. Antibiotic resistance threats in the United States, 2013. [cited 2018 Apr 9]. Available from: https://www.cdc.gov/drugresistance/threat-report-2013/index.html
- Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175–1184.
- Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.
- Kalil AC, Van Schooneveld TC, Fey PD, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with staphylococcus aureus bloodstream infections a systematic review and meta-analysis. JAMA. 2014;312:1552–1564.
- Gudiol C, Cuervo G, Shaw E, et al. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia. Expert Opin Pharmacother. 2017;18:1947–1963.
- Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923–929.
- Britt NS, Potter EM, Patel N, et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis. 2015;61:871–878.
- Zhao M, Liang L, Ji L, et al. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycinresistant enterococcal bloodstream infections: a meta-analysis. Int J Antimicrob Agents. 2016;48:231–238.
- Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010;16:555–562.
- Sader HS, Farrell DJ, Flamm RK, et al. Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). J Glob Antimicrob Resist. 2015;3:161–165.
- Leone S, Noviello S, Boccia G, et al. Methicillin-resistant Staphylococcus aureus infections: role of daptomycin/β-lactams combination. Infez Med. 2015;23:99–104.
- Zasowski EJ, Trinh TD, Claeys KC, et al. multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61:2.
- Noviello S, Ianniello F, Leone S, et al. In vitro activity of tigecycline: MICS, MBCs, time-kill curves and post-antibiotic effect. J Chemother. 2008;20:577–580.
- Fiore M, Maraolo AE, Gentile I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol. 2017;9:1166–1175.
- Fiore M, Andreana L, Leone S. Treatment of spontaneous bacterial peritonitis: beyond the current international guidelines. Liver Int. 2016;36:918.
- Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology. 2016;63:1299–1309.
- Blazewicz I, Jaskiewicz M, Piechowicz L, et al. Increasing rate of daptomycin non-susceptible strains of Staphylococcus aureus in patients with atopic dermatitis. Postepy Dermatol Alergol. 2017;34:547–552.
- DiPippo AJ, Tverdek FP, Tarrand JJ, et al. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure. J Infect. 2017;74:243–247.
- Ballester F, Pujol I, Cueto P, et al. Emergence of daptomycin-resistant Enterococcus faecium in a critically ill patient with postoperative intra-abdominal sepsis. Rev Esp Quimioter. 2015 Apr;28(2):109–110.